In a groundbreaking move for the medical field, Axonics, Inc. has announced that its recharge-free sacral neuromodulation (SNM) system has received regulatory approval from the Therapeutic Goods Administration (TGA) in Australia. This approval marks a significant breakthrough in the treatment of overactive bladder in adults, providing relief for Australians suffering from bladder and bowel dysfunction.